25 XP   0   0   10

Alaunos Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Alaunos together

PenkeI guess you are interested in Alaunos Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alaunos Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alaunos Therapeutics Inc

I send you an email if I find something interesting about Alaunos Therapeutics Inc.

Quick analysis of Alaunos (30 sec.)










What can you expect buying and holding a share of Alaunos? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
17.5%

What is your share worth?

Current worth
$0.39
Expected worth in 1 year
$-1.06
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-1.45
Return On Investment
-103.5%

For what price can you sell your share?

Current Price per Share
$1.40
Expected price per share
$1.05 - $2.03
How sure are you?
50%

1. Valuation of Alaunos (5 min.)




Live pricePrice per Share (EOD)

$1.40

Intrinsic Value Per Share

$-25.86 - $-10.86

Total Value Per Share

$-25.47 - $-10.47

2. Growth of Alaunos (5 min.)




Is Alaunos growing?

Current yearPrevious yearGrowGrow %
How rich?$6.3m$35m-$23m-191.4%

How much money is Alaunos making?

Current yearPrevious yearGrowGrow %
Making money-$8.2m-$9.5m$1.3m16.6%
Net Profit Margin-446,981.3%-22,347.0%--

How much money comes from the company's main activities?

3. Financial Health of Alaunos (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#730 / 1019

Most Revenue
#716 / 1019

Most Profit
#517 / 1019

Most Efficient
#1016 / 1019

What can you expect buying and holding a share of Alaunos? (5 min.)

Welcome investor! Alaunos's management wants to use your money to grow the business. In return you get a share of Alaunos.

What can you expect buying and holding a share of Alaunos?

First you should know what it really means to hold a share of Alaunos. And how you can make/lose money.

Speculation

The Price per Share of Alaunos is $1.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alaunos.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alaunos, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.39. Based on the TTM, the Book Value Change Per Share is $-0.36 per quarter. Based on the YOY, the Book Value Change Per Share is $0.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alaunos.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.49-35.0%-0.51-36.7%-0.32-23.0%-0.24-17.0%-0.20-14.5%
Usd Book Value Change Per Share0.000.0%-0.36-25.9%0.4028.8%0.00-0.2%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.3%0.010.7%
Usd Total Gains Per Share0.000.0%-0.36-25.9%0.4028.8%0.000.1%0.010.7%
Usd Price Per Share1.81-0.63-1.06-2.11-3.91-
Price to Earnings Ratio-0.92--0.31--4.42--5.37--9.50-
Price-to-Total Gains Ratio4,948.32-1,236.72--19.12-229.84-90.30-
Price to Book Ratio4.60-1.33-4.69-4.37-9.75-
Price-to-Total Gains Ratio4,948.32-1,236.72--19.12-229.84-90.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.4
Number of shares714
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.360.00
Usd Total Gains Per Share-0.360.00
Gains per Quarter (714 shares)-258.650.95
Gains per Year (714 shares)-1,034.583.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1035-104514-10-6
20-2069-208027-19-2
30-3104-311541-292
40-4138-415054-396
50-5173-518568-4910
60-6207-622081-5814
70-7242-725595-6818
80-8277-8290108-7822
90-9311-9325122-8826
100-10346-10360135-9730

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%2.090.00.02.2%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%10.030.00.025.0%25.065.02.027.2%
Dividend per Share0.00.04.00.0%1.00.011.08.3%2.00.018.010.0%7.00.033.017.5%7.00.085.07.6%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%10.030.00.025.0%25.065.02.027.2%

Fundamentals of Alaunos

About Alaunos Therapeutics Inc

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

Fundamental data was last updated by Penke on 2024-04-09 19:48:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Alaunos Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alaunos earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • A Net Profit Margin of -784,300.0% means that $-7,843.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alaunos Therapeutics Inc:

  • The MRQ is -784,300.0%. The company is making a huge loss. -2
  • The TTM is -446,981.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-784,300.0%TTM-446,981.3%-337,318.8%
TTM-446,981.3%YOY-22,347.0%-424,634.3%
TTM-446,981.3%5Y-94,151.2%-352,830.0%
5Y-94,151.2%10Y-48,734.6%-45,416.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-784,300.0%-196.9%-784,103.1%
TTM-446,981.3%-211.2%-446,770.1%
YOY-22,347.0%-279.3%-22,067.7%
5Y-94,151.2%-436.8%-93,714.4%
10Y-48,734.6%-599.3%-48,135.3%
1.1.2. Return on Assets

Shows how efficient Alaunos is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • -94.9% Return on Assets means that Alaunos generated $-0.95 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alaunos Therapeutics Inc:

  • The MRQ is -94.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -66.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-94.9%TTM-66.2%-28.7%
TTM-66.2%YOY-15.4%-50.8%
TTM-66.2%5Y-27.7%-38.5%
5Y-27.7%10Y-23.7%-3.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-94.9%-13.6%-81.3%
TTM-66.2%-12.9%-53.3%
YOY-15.4%-11.9%-3.5%
5Y-27.7%-14.2%-13.5%
10Y-23.7%-16.2%-7.5%
1.1.3. Return on Equity

Shows how efficient Alaunos is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • -124.4% Return on Equity means Alaunos generated $-1.24 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alaunos Therapeutics Inc:

  • The MRQ is -124.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -87.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-124.4%TTM-87.6%-36.8%
TTM-87.6%YOY-27.7%-59.8%
TTM-87.6%5Y-37.3%-50.3%
5Y-37.3%10Y-38.1%+0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-124.4%-17.0%-107.4%
TTM-87.6%-16.1%-71.5%
YOY-27.7%-15.4%-12.3%
5Y-37.3%-20.0%-17.3%
10Y-38.1%-21.1%-17.0%

1.2. Operating Efficiency of Alaunos Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alaunos is operating .

  • Measures how much profit Alaunos makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • An Operating Margin of -336,000.0% means the company generated $-3,360.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alaunos Therapeutics Inc:

  • The MRQ is -336,000.0%. The company is operating very inefficient. -2
  • The TTM is -133,687.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-336,000.0%TTM-133,687.5%-202,312.5%
TTM-133,687.5%YOY-19,436.9%-114,250.6%
TTM-133,687.5%5Y-30,905.0%-102,782.5%
5Y-30,905.0%10Y-17,301.9%-13,603.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-336,000.0%-282.4%-335,717.6%
TTM-133,687.5%-225.8%-133,461.7%
YOY-19,436.9%-288.4%-19,148.5%
5Y-30,905.0%-475.2%-30,429.8%
10Y-17,301.9%-624.7%-16,677.2%
1.2.2. Operating Ratio

Measures how efficient Alaunos is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3,361.00 means that the operating costs are $3,361.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 3,361.000. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2,290.750. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3,361.000TTM2,290.750+1,070.250
TTM2,290.750YOY213.224+2,077.526
TTM2,290.7505Y503.646+1,787.104
5Y503.64610Y269.776+233.869
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3,361.0002.994+3,358.006
TTM2,290.7503.247+2,287.503
YOY213.2243.766+209.458
5Y503.6465.675+497.971
10Y269.7767.857+261.919

1.3. Liquidity of Alaunos Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alaunos is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.22 means the company has $4.22 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 4.223. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.729. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.223TTM3.729+0.494
TTM3.729YOY2.111+1.618
TTM3.7295Y5.471-1.742
5Y5.47110Y6.097-0.626
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2233.930+0.293
TTM3.7294.251-0.522
YOY2.1115.436-3.325
5Y5.4716.045-0.574
10Y6.0976.383-0.286
1.3.2. Quick Ratio

Measures if Alaunos is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • A Quick Ratio of 3.10 means the company can pay off $3.10 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 3.100. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.320. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.100TTM2.320+0.779
TTM2.320YOY1.629+0.691
TTM2.3205Y4.572-2.252
5Y4.57210Y5.130-0.558
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1003.629-0.529
TTM2.3204.065-1.745
YOY1.6295.390-3.761
5Y4.5725.993-1.421
10Y5.1306.277-1.147

1.4. Solvency of Alaunos Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alaunos assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alaunos to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Alaunos assets are financed with 23.7% credit (debt) and the remaining percentage (100% - 23.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.237. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.246. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.237TTM0.246-0.009
TTM0.246YOY0.445-0.199
TTM0.2465Y0.302-0.056
5Y0.30210Y0.455-0.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2370.332-0.095
TTM0.2460.333-0.087
YOY0.4450.268+0.177
5Y0.3020.366-0.064
10Y0.4550.390+0.065
1.4.2. Debt to Equity Ratio

Measures if Alaunos is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.0% means that company has $0.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.310. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.327. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.310TTM0.327-0.017
TTM0.327YOY0.817-0.490
TTM0.3275Y0.450-0.123
5Y0.45010Y0.991-0.541
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3100.380-0.070
TTM0.3270.389-0.062
YOY0.8170.334+0.483
5Y0.4500.432+0.018
10Y0.9910.465+0.526

2. Market Valuation of Alaunos Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alaunos generates.

  • Above 15 is considered overpriced but always compare Alaunos to the Biotechnology industry mean.
  • A PE ratio of -0.92 means the investor is paying $-0.92 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is -0.715. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.924. Based on the earnings, the company is expensive. -2
  • The TTM is -0.313. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.715MRQ-0.924+0.209
MRQ-0.924TTM-0.313-0.610
TTM-0.313YOY-4.424+4.110
TTM-0.3135Y-5.373+5.060
5Y-5.37310Y-9.497+4.123
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.715-2.426+1.711
MRQ-0.924-2.552+1.628
TTM-0.313-2.656+2.343
YOY-4.424-4.143-0.281
5Y-5.373-6.252+0.879
10Y-9.497-6.108-3.389
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is -0.759. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.981. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.347. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.759MRQ-0.981+0.222
MRQ-0.981TTM-0.347-0.634
TTM-0.347YOY-5.932+5.585
TTM-0.3475Y-8.012+7.665
5Y-8.01210Y-10.561+2.550
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.759-3.199+2.440
MRQ-0.981-3.259+2.278
TTM-0.347-3.552+3.205
YOY-5.932-5.617-0.315
5Y-8.012-8.326+0.314
10Y-10.561-8.689-1.872
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alaunos is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.60 means the investor is paying $4.60 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is 3.554. Based on the equity, the company is fair priced.
  • The MRQ is 4.595. Based on the equity, the company is fair priced.
  • The TTM is 1.325. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.554MRQ4.595-1.041
MRQ4.595TTM1.325+3.270
TTM1.325YOY4.692-3.367
TTM1.3255Y4.367-3.042
5Y4.36710Y9.755-5.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.5541.947+1.607
MRQ4.5952.116+2.479
TTM1.3252.095-0.770
YOY4.6922.836+1.856
5Y4.3673.443+0.924
10Y9.7553.791+5.964
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alaunos Therapeutics Inc.

3.1. Institutions holding Alaunos Therapeutics Inc

Institutions are holding 17.156% of the shares of Alaunos Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Discovery Capital Management LLC6.42570.361815461829-181194-1.1583
2023-09-30MSD Partners, L.P.6.29670.16111515151600
2023-09-30Vanguard Group Inc3.9226094387623270783.5897
2023-09-30BlackRock Inc2.065504970232-102148-2.0138
2023-09-30Geode Capital Management, LLC0.899102163473-90953-4.0344
2023-09-30State Street Corporation0.3149075782600
2023-09-30Advisor Group Holdings, Inc.0.26220.0001630945204003.3413
2023-09-30Commerce Bank NA/MO0.19080.000545900000
2023-09-30Northern Trust Corp0.1810435575-4455-1.0124
2023-09-30MAGNOLIA CAPITAL ADVISORS LLC0.17990.03144329694329690
2023-09-30Two Sigma Advisers, LLC0.17920.0002431192-207100-32.446
2023-09-30Morgan Stanley - Brokerage Accounts0.13610327468-279778-46.0733
2023-09-30Two Sigma Investments LLC0.12850.0001309217-107473-25.7921
2023-09-30UBS Group AG0.10880261712119284.7753
2023-12-31Allred Capital Management, LLC0.10510.007825300000
2023-09-30Group One Trading, LP0.09680.0001232806-24734-9.6039
2023-09-30Susquehanna International Group, LLP0.0510122664-366297-74.9133
2023-09-30Wells Fargo & Co0.04780114949-30533-20.9875
2023-09-30Charles Schwab Investment Management Inc0.0458011029700
2023-09-30Franklin Resources Inc0.04490107948-27933-20.557
Total 21.68240.563152173380-630223-1.2%

3.2. Funds holding Alaunos Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Extended Market Index0.45330.0005109076900
2023-09-30BlackRock Extended Mkt Composite0.21340.000551350700
2023-12-31BlackRock Extended Equity Market K0.18620.0002447992-902-0.2009
2024-02-29Vanguard Total Stock Mkt Idx Inv2.5180.0001403930400.0099
2024-01-31Fidelity Total Market Index0.14810.000135646100
2024-01-31Fidelity Series Total Market Index0.12980.000131235100
2024-01-31Fidelity Nasdaq Composite Index0.12530.000430145400
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.27620.0004204718200.0098
2023-12-31NT Ext Equity Mkt Idx Fd - L0.08460.000320361800
2023-12-31Northern Trust Extended Eq Market Idx0.08460.000320361800
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06770.000216298900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05440.00021309032460.1883
2024-01-31Spartan Total Market Index Pool E0.04770.000111477300
2023-12-31SSgA U.S. Extended Market Index Class I0.04640.000311171700
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.04620111142-5703860-98.0887
2023-12-31BlackRock U.S. Equity Market F0.04320.00011039241870.1803
2023-12-31Franklin U.S. Small Cap Equity I0.04190.007510085000
2024-01-31Spartan Extended Market Index Pool E0.03280.00067902900
2023-12-31Extended Equity Market Fund M0.0230.00025539326364.9965
2023-12-31SSgA U.S. Total Market Index Strategy0.0134032225-745-2.2596
Total 5.63620.01215041363-5702378-113.1%

3.3. Insider Transactions

Insiders are holding 4.394% of the shares of Alaunos Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-01Kevin S Sr. BoyleSELL45342.1

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Alaunos Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.000-0.362+99134%0.404-100%-0.003+1031%-0.001+254%
Book Value Per Share--0.3940.752-48%1.147-66%0.663-41%0.489-19%
Current Ratio--4.2233.729+13%2.111+100%5.471-23%6.097-31%
Debt To Asset Ratio--0.2370.246-4%0.445-47%0.302-22%0.455-48%
Debt To Equity Ratio--0.3100.327-5%0.817-62%0.450-31%0.991-69%
Dividend Per Share----0%0.000-100%0.005-100%0.010-100%
Eps---0.490-0.514+5%-0.322-34%-0.237-52%-0.203-59%
Free Cash Flow Per Share---0.461-0.441-4%-0.277-40%-0.186-60%-0.132-71%
Free Cash Flow To Equity Per Share---0.461-0.628+36%-0.246-47%-0.168-63%-0.084-82%
Gross Profit Margin--0.9690.992-2%1.173-17%1.183-18%1.091-11%
Intrinsic Value_10Y_max---10.859--------
Intrinsic Value_10Y_min---25.861--------
Intrinsic Value_1Y_max---0.609--------
Intrinsic Value_1Y_min---1.317--------
Intrinsic Value_3Y_max---2.196--------
Intrinsic Value_3Y_min---5.084--------
Intrinsic Value_5Y_max---4.222--------
Intrinsic Value_5Y_min---10.058--------
Market Cap22417500.000-29%28982625.00010088135.470+187%164266224.680-82%378678279.053-92%558474227.493-95%
Net Profit Margin---7843.000-4469.813-43%-223.470-97%-941.512-88%-487.346-94%
Operating Margin---3360.000-1336.875-60%-194.369-94%-309.050-91%-173.019-95%
Operating Ratio--3361.0002290.750+47%213.224+1476%503.646+567%269.776+1146%
Pb Ratio3.554-29%4.5951.325+247%4.692-2%4.367+5%9.755-53%
Pe Ratio-0.715+23%-0.924-0.313-66%-4.424+379%-5.373+482%-9.497+928%
Price Per Share1.400-29%1.8100.630+187%1.060+71%2.108-14%3.915-54%
Price To Free Cash Flow Ratio-0.759+23%-0.981-0.347-65%-5.932+505%-8.012+717%-10.561+976%
Price To Total Gains Ratio3827.431-29%4948.3211236.716+300%-19.124+100%229.845+2053%90.297+5380%
Quick Ratio--3.1002.320+34%1.629+90%4.572-32%5.130-40%
Return On Assets---0.949-0.662-30%-0.154-84%-0.277-71%-0.237-75%
Return On Equity---1.244-0.876-30%-0.277-78%-0.373-70%-0.381-69%
Total Gains Per Share--0.000-0.362+99134%0.404-100%0.001-73%0.009-96%
Usd Book Value--6307000.00012041000.000-48%35089250.000-82%66955050.000-91%53428825.000-88%
Usd Book Value Change Per Share--0.000-0.362+99134%0.404-100%-0.003+1031%-0.001+254%
Usd Book Value Per Share--0.3940.752-48%1.147-66%0.663-41%0.489-19%
Usd Dividend Per Share----0%0.000-100%0.005-100%0.010-100%
Usd Eps---0.490-0.514+5%-0.322-34%-0.237-52%-0.203-59%
Usd Free Cash Flow---7385000.000-7070500.000-4%-7772750.000+5%-11482500.000+55%-10817475.000+46%
Usd Free Cash Flow Per Share---0.461-0.441-4%-0.277-40%-0.186-60%-0.132-71%
Usd Free Cash Flow To Equity Per Share---0.461-0.628+36%-0.246-47%-0.168-63%-0.084-82%
Usd Market Cap22417500.000-29%28982625.00010088135.470+187%164266224.680-82%378678279.053-92%558474227.493-95%
Usd Price Per Share1.400-29%1.8100.630+187%1.060+71%2.108-14%3.915-54%
Usd Profit---7843000.000-8233750.000+5%-9596500.000+22%-17244900.000+120%-19330675.000+146%
Usd Revenue--1000.0001500.000-33%730500.000-100%166300.000-99%555675.000-100%
Usd Total Gains Per Share--0.000-0.362+99134%0.404-100%0.001-73%0.009-96%
 EOD+2 -6MRQTTM+19 -15YOY+9 -275Y+8 -2810Y+9 -27

4.2. Fundamental Score

Let's check the fundamental score of Alaunos Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.715
Price to Book Ratio (EOD)Between0-13.554
Net Profit Margin (MRQ)Greater than0-7,843.000
Operating Margin (MRQ)Greater than0-3,360.000
Quick Ratio (MRQ)Greater than13.100
Current Ratio (MRQ)Greater than14.223
Debt to Asset Ratio (MRQ)Less than10.237
Debt to Equity Ratio (MRQ)Less than10.310
Return on Equity (MRQ)Greater than0.15-1.244
Return on Assets (MRQ)Greater than0.05-0.949
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Alaunos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.298
Ma 20Greater thanMa 501.760
Ma 50Greater thanMa 1001.873
Ma 100Greater thanMa 2001.660
OpenGreater thanClose1.560
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets8,263
Total Liabilities1,956
Total Stockholder Equity6,307
 As reported
Total Liabilities 1,956
Total Stockholder Equity+ 6,307
Total Assets = 8,263

Assets

Total Assets8,263
Total Current Assets8,261
Long-term Assets2
Total Current Assets
Cash And Cash Equivalents 6,062
Net Receivables 1
Other Current Assets 2,198
Total Current Assets  (as reported)8,261
Total Current Assets  (calculated)8,261
+/-0
Long-term Assets
Property Plant Equipment 2
Long-term Assets  (as reported)2
Long-term Assets  (calculated)2
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,956
Long-term Liabilities0
Total Stockholder Equity6,307
Total Current Liabilities
Accounts payable 616
Other Current Liabilities 1,340
Total Current Liabilities  (as reported)1,956
Total Current Liabilities  (calculated)1,956
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock16
Retained Earnings -915,767
Other Stockholders Equity 922,058
Total Stockholder Equity (as reported)6,307
Total Stockholder Equity (calculated)6,307
+/-0
Other
Cash and Short Term Investments 6,062
Common Stock Shares Outstanding 16,012
Liabilities and Stockholders Equity 8,263
Net Debt -6,062
Net Working Capital 6,305



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-09-302003-06-302003-03-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-09-302000-06-30
> Total Assets 
0
0
0
10
4
3
6
2
1
1
0
0
0
0
0
0
0
1
11,312
9,492
6,308
37,775
35,295
29,512
54,185
48,521
42,801
36,726
29,004
22,458
16,815
12,573
7,873
5,431
8,103
49,736
45,840
74,456
67,450
61,520
130,862
132,821
122,276
108,108
140,873
122,380
105,640
83,404
63,346
45,603
29,478
71,754
63,325
55,348
49,109
45,237
131,648
124,038
173,361
153,724
141,682
128,012
117,122
106,348
94,494
126,813
116,559
105,606
87,461
76,383
66,801
95,051
83,503
73,173
117,949
109,114
198,279
181,679
165,894
146,345
128,472
106,765
113,762
94,865
84,991
73,931
67,344
64,937
48,638
27,927
19,440
8,263
8,263
8,2638,26319,44027,92748,63864,93767,34473,93184,99194,865113,762106,765128,472146,345165,894181,679198,279109,114117,94973,17383,50395,05166,80176,38387,461105,606116,559126,81394,494106,348117,122128,012141,682153,724173,361124,038131,64845,23749,10955,34863,32571,75429,47845,60363,34683,404105,640122,380140,873108,108122,276132,821130,86261,52067,45074,45645,84049,7368,1035,4317,87312,57316,81522,45829,00436,72642,80148,52154,18529,51235,29537,7756,3089,49211,3121000000011263410000
   > Total Current Assets 
0
0
0
9
3
1
5
1
0
0
0
0
0
0
0
0
0
1
10,950
9,093
5,875
37,349
34,813
28,873
53,275
47,508
41,626
35,528
27,823
21,325
15,769
11,706
7,006
4,696
7,450
49,193
45,356
73,941
66,823
60,816
129,971
131,298
120,417
106,105
138,811
119,442
102,581
80,276
60,561
43,030
27,275
70,297
62,001
54,024
47,814
44,087
130,603
123,080
172,480
152,521
140,389
126,709
115,677
104,884
92,750
125,130
114,888
90,783
72,115
52,993
47,161
84,285
74,093
65,859
115,599
105,492
191,620
173,176
155,071
130,589
112,710
89,407
96,554
78,831
69,772
61,361
55,505
53,799
38,184
18,778
12,869
8,261
8,261
8,2618,26112,86918,77838,18453,79955,50561,36169,77278,83196,55489,407112,710130,589155,071173,176191,620105,492115,59965,85974,09384,28547,16152,99372,11590,783114,888125,13092,750104,884115,677126,709140,389152,521172,480123,080130,60344,08747,81454,02462,00170,29727,27543,03060,56180,276102,581119,442138,811106,105120,417131,298129,97160,81666,82373,94145,35649,1937,4504,6967,00611,70615,76921,32527,82335,52841,62647,50853,27528,87334,81337,3495,8759,09310,950100000000015139000
       Cash And Cash Equivalents 
0
0
0
6
1
0
5
0
0
0
0
0
0
0
0
0
0
1
10,741
8,881
1,079
32,577
32,962
26,855
52,701
46,690
40,939
35,029
27,487
21,087
15,192
11,379
6,768
4,543
7,080
48,839
45,044
73,662
66,471
60,392
124,037
130,282
118,933
104,713
128,008
110,391
95,333
73,306
55,655
38,932
23,631
68,204
60,385
53,001
46,122
42,803
129,684
118,550
163,843
140,717
124,846
109,004
94,683
81,053
66,447
97,194
84,406
70,946
51,108
40,404
31,728
61,729
51,487
43,563
88,419
79,741
171,002
153,521
135,471
115,069
100,056
76,746
91,725
76,054
68,255
60,011
37,807
39,058
23,496
18,317
11,944
6,062
6,062
6,0626,06211,94418,31723,49639,05837,80760,01168,25576,05491,72576,746100,056115,069135,471153,521171,00279,74188,41943,56351,48761,72931,72840,40451,10870,94684,40697,19466,44781,05394,683109,004124,846140,717163,843118,550129,68442,80346,12253,00160,38568,20423,63138,93255,65573,30695,333110,391128,008104,713118,933130,282124,03760,39266,47173,66245,04448,8397,0804,5436,76811,37915,19221,08727,48735,02940,93946,69052,70126,85532,96232,5771,0798,88110,741100000000005016000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
4,553
1,536
1,555
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000001,5551,5364,5534,50000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
0
79
79
0
0
13
58
72
31
449
145
27
32
208
145
62
89
369
446
1,060
15
25
21
67
44
13
19
18
663
1,021
1,864
854
1,460
3,441
3,330
782
4,072
5,428
4,665
5,006
7,626
1,510
1,111
0
1,111
2,911
4
0
4
0
1
1
1104042,9111,11101,1111,5107,6265,0064,6655,4284,0727823,3303,4411,4608541,8641,02166318191344672125151,060446369896214520832271454493172581300797905,0000000000000000000000000000000000010000000
       Other Current Assets 
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
210
212
296
219
315
463
574
818
687
499
336
238
577
327
238
153
370
354
312
279
352
424
934
1,016
1,405
1,313
10,803
9,051
7,235
6,912
4,834
4,067
3,195
1,948
1,589
991
1,484
1,139
857
4,441
8,268
11,358
14,483
17,690
20,969
23,810
26,236
27,892
30,469
19,818
20,989
11,926
14,412
20,692
21,752
20,836
23,739
22,421
19,836
15,583
14,172
10,855
7,648
5,035
3,319
1,666
1,517
1,350
14,787
799
750
457
925
2,198
2,198
2,1982,19892545775079914,7871,3501,5171,6663,3195,0357,64810,85514,17215,58319,83622,42123,73920,83621,75220,69214,41211,92620,98919,81830,46927,89226,23623,81020,96917,69014,48311,3588,2684,4418571,1391,4849911,5891,9483,1954,0674,8346,9127,2359,05110,8031,3131,4051,016934424352279312354370153238327577238336499687818574463315219296212210000000000000020000
   > Long-term Assets 
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
362
400
433
427
482
639
910
1,013
1,175
1,199
1,181
1,133
1,046
867
867
735
653
543
484
515
627
704
891
1,523
1,859
2,003
2,062
2,938
3,059
3,128
2,785
2,573
2,203
1,457
1,324
1,324
1,295
1,150
1,045
958
881
1,203
1,293
1,303
1,445
1,464
1,744
1,683
1,671
14,823
15,346
23,390
19,640
10,766
9,410
7,314
2,350
3,622
6,659
8,503
10,823
15,756
15,762
17,358
17,208
16,034
15,219
12,570
11,839
11,138
10,454
9,149
6,571
2
2
226,5719,14910,45411,13811,83912,57015,21916,03417,20817,35815,76215,75610,8238,5036,6593,6222,3507,3149,41010,76619,64023,39015,34614,8231,6711,6831,7441,4641,4451,3031,2931,2038819581,0451,1501,2951,3241,3241,4572,2032,5732,7853,1283,0592,9382,0622,0031,8591,5238917046275154845436537358678671,0461,1331,1811,1991,1751,013910639482427433400362000000000011111000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
233
270
302
295
295
451
601
661
719
746
727
675
589
489
489
406
324
255
196
216
230
253
443
549
886
1,141
1,177
1,982
2,108
1,994
1,909
1,713
1,336
801
679
683
654
531
426
321
262
581
667
682
825
843
1,124
1,062
1,047
1,211
1,244
1,332
1,344
1,097
2,556
2,315
2,111
3,382
5,863
7,629
9,947
14,881
15,447
16,977
16,841
15,361
14,551
12,028
11,297
10,596
9,912
8,648
6,571
2
2
226,5718,6489,91210,59611,29712,02814,55115,36116,84116,97715,44714,8819,9477,6295,8633,3822,1112,3152,5561,0971,3441,3321,2441,2111,0471,0621,1248438256826675812623214265316546836798011,3361,7131,9091,9942,1081,9821,1771,141886549443253230216196255324406489489589675727746719661601451295295302270233000000000000000000
       Intangible Assets 
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000000000000000000000011111000
       Other Assets 
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
875
315
381
367
673
668
542
542
542
0
501
0
0
0
00050105425425426686733673813158750000000000000000000000000000000000000000000000000000000000000000000000000100000
> Total Liabilities 
0
0
0
14
12
6
0
2
7
18
15
19
26
14
15
21
18
10
1,748
2,290
2,024
2,677
3,321
2,979
3,398
3,867
5,106
6,357
6,790
6,242
5,761
5,834
4,136
3,753
4,180
21,632
34,454
19,738
25,246
30,967
48,910
48,693
38,164
36,501
43,173
46,744
46,612
34,959
25,453
26,271
25,847
22,371
21,593
17,632
12,632
11,396
11,045
13,597
79,520
66,353
63,869
180,002
59,726
183,646
59,955
56,853
57,289
202,412
61,571
61,190
62,786
9,487
9,287
11,178
11,823
109,114
17,942
18,265
20,976
22,363
22,831
18,484
45,055
36,808
35,869
33,751
35,231
26,382
19,129
6,277
5,540
1,956
1,956
1,9561,9565,5406,27719,12926,38235,23133,75135,86936,80845,05518,48422,83122,36320,97618,26517,942109,11411,82311,1789,2879,48762,78661,19061,571202,41257,28956,85359,955183,64659,726180,00263,86966,35379,52013,59711,04511,39612,63217,63221,59322,37125,84726,27125,45334,95946,61246,74443,17336,50138,16448,69348,91030,96725,24619,73834,45421,6324,1803,7534,1365,8345,7616,2426,7906,3575,1063,8673,3982,9793,3212,6772,0242,2901,74810182115142619151872061214000
   > Total Current Liabilities 
0
0
0
10
8
0
0
0
0
18
15
19
26
14
15
21
18
10
1,748
2,255
1,988
2,640
3,281
2,938
3,357
3,824
5,070
6,306
6,731
6,181
5,701
5,776
3,956
3,375
3,514
3,095
2,833
2,305
4,106
3,612
6,544
8,691
11,770
13,363
14,330
17,776
21,736
18,864
20,362
20,997
13,362
7,791
7,354
10,788
11,700
10,826
10,492
13,110
29,627
18,123
17,274
16,035
15,744
15,809
17,464
15,988
18,189
20,856
10,062
9,314
60,183
9,483
8,339
10,400
11,176
12,526
16,579
17,112
19,321
18,368
18,961
13,593
28,173
16,041
21,234
26,775
32,869
24,166
17,063
5,052
4,676
1,956
1,956
1,9561,9564,6765,05217,06324,16632,86926,77521,23416,04128,17313,59318,96118,36819,32117,11216,57912,52611,17610,4008,3399,48360,1839,31410,06220,85618,18915,98817,46415,80915,74416,03517,27418,12329,62713,11010,49210,82611,70010,7887,3547,79113,36220,99720,36218,86421,73617,77614,33013,36311,7708,6916,5443,6124,1062,3052,8333,0953,5143,3753,9565,7765,7016,1816,7316,3065,0703,8243,3572,9383,2812,6401,9882,2551,7481018211514261915180000810000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-40,112
146
644
660
677
774
828
838
866
819
759
765
12,747
8,597
14,738
20,576
23,210
17,323
11,563
339
307
0
0
0030733911,56317,32323,21020,57614,7388,59712,747765759819866838828774677660644146-40,1120000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,037
7,868
13,993
20,051
22,668
16,765
10,988
0
0
0
0
000010,98816,76522,66820,05113,9937,86812,0370000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
1
0
0
8
5
5
0
10
10
477
836
545
627
1,144
776
956
1,489
1,638
2,909
2,648
1,900
2,228
2,639
1,621
1,606
1,559
1,789
1,468
1,143
1,088
1,031
1,853
1,784
2,160
1,727
1,984
1,470
4,248
1,509
983
1,165
891
422
578
447
1,953
2,004
779
3,143
4,154
2,008
1,908
2,031
1,814
156
226
81
1,524
4,417
606
588
1,269
707
859
941
926
906
396
1,082
2,619
960
4,190
982
1,463
1,368
605
474
1,984
1,389
1,380
1,479
1,298
616
616
6166161,2981,4791,3801,3891,9844746051,3681,4639824,1909602,6191,0823969069269418597071,2695886064,4171,524812261561,8142,0311,9082,0084,1543,1437792,0041,9534475784228911,1659831,5094,2481,4701,9841,7272,1601,7841,8531,0311,0881,1431,4681,7891,5591,6061,6212,6392,2281,9002,6482,9091,6381,4899567761,14462754583647710100558001000000000
       Other Current Liabilities 
0
0
0
10
8
0
0
0
0
17
15
19
18
9
10
21
7
0
1,271
1,419
1,443
2,013
2,137
2,162
2,402
2,335
3,432
3,396
4,083
4,281
3,473
3,137
2,335
1,730
1,909
1,261
1,322
1,139
2,978
2,538
3,862
6,084
8,789
10,821
11,534
15,502
16,682
16,555
18,579
19,032
11,671
6,569
5,976
8,008
8,047
7,462
8,625
9,151
18,540
9,254
8,877
7,615
7,541
9,264
10,849
9,518
10,276
10,050
8,980
8,726
49,513
8,776
644
8,799
9,573
10,846
15,355
15,192
15,836
16,589
14,012
11,846
13,963
6,076
5,891
5,725
7,675
5,454
4,120
3,234
3,071
0
1,340
1,34003,0713,2344,1205,4547,6755,7255,8916,07613,96311,84614,01216,58915,83615,19215,35510,8469,5738,7996448,77649,5138,7268,98010,05010,2769,51810,8499,2647,5417,6158,8779,25418,5409,1518,6257,4628,0478,0085,9766,56911,67119,03218,57916,55516,68215,50211,53410,8218,7896,0843,8622,5382,9781,1391,3221,2611,9091,7302,3353,1373,4734,2814,0833,3963,4322,3352,4022,1622,1372,0131,4431,4191,2710721109181915170000810000
   > Long-term Liabilities 
0
0
0
4
4
6
0
2
7
1
0
0
8
5
5
0
10
10
477
36
36
37
40
41
41
44
36
51
59
60
61
58
180
378
666
18,537
31,621
17,433
21,140
27,355
42,366
40,002
26,394
23,138
28,843
28,968
24,876
16,095
5,091
5,274
12,485
14,580
14,239
6,844
932
570
553
487
49,893
48,230
46,595
163,967
43,982
42,516
42,491
40,865
39,100
37,564
51,509
51,876
2,603
4
948
778
647
1,578
1,363
1,153
1,655
3,995
3,870
4,891
16,882
20,767
14,635
6,976
2,362
2,216
2,066
1,225
864
0
0
008641,2252,0662,2162,3626,97614,63520,76716,8824,8913,8703,9951,6551,1531,3631,57864777894842,60351,87651,50937,56439,10040,86542,49142,51643,982163,96746,59548,23049,8934875535709326,84414,23914,58012,4855,2745,09116,09524,87628,96828,84323,13826,39440,00242,36627,35521,14017,43331,62118,5376663781805861605951364441414037363647710100558001720644000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,323
4,472
0
0
0
0
0
0
0
00000004,47210,323000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
28
28
28
0
0
0
0
0
000002828280-100000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-4
-8
-14
-3
-9
-11
-17
-15
-19
-26
-14
-15
-21
-18
-9
9,564
7,202
4,284
35,098
31,974
26,533
50,787
44,654
37,695
30,370
22,214
16,217
11,053
6,739
3,737
1,678
3,923
28,104
11,386
54,718
42,204
30,553
81,952
84,128
84,112
71,607
97,700
75,636
59,028
48,445
37,893
19,332
3,631
49,383
41,732
37,716
36,477
33,841
120,603
110,441
93,841
87,371
77,813
-51,990
57,396
-77,298
34,539
69,960
59,270
-96,806
25,890
15,193
4,015
85,564
74,216
61,995
106,126
95,010
180,337
163,414
144,918
123,982
105,641
88,281
68,707
58,057
49,122
40,180
32,113
38,555
29,509
21,650
13,900
6,307
6,307
6,3076,30713,90021,65029,50938,55532,11340,18049,12258,05768,70788,281105,641123,982144,918163,414180,33795,010106,12661,99574,21685,5644,01515,19325,890-96,80659,27069,96034,539-77,29857,396-51,99077,81387,37193,841110,441120,60333,84136,47737,71641,73249,3833,63119,33237,89348,44559,02875,63697,70071,60784,11284,12881,95230,55342,20454,71811,38628,1043,9231,6783,7376,73911,05316,21722,21430,37037,69544,65450,78726,53331,97435,0984,2847,2029,564-9-18-21-15-14-26-19-15-17-11-9-3-14-8-4000
   Common Stock
0
0
0
89
89
0
0
120
120
120
130
130
130
156
156
156
169
184
7
7
7
15
15
15
21
21
21
21
21
21
21
22
22
22
26
42
42
49
49
48
66
68
68
69
80
80
80
83
84
84
84
100
101
101
103
104
128
131
131
132
132
132
132
132
132
142
142
143
142
142
142
161
162
162
181
182
214
214
214
215
215
216
216
216
216
216
216
240
241
241
241
0
16
160241241241240216216216216216216215215214214214182181162162161142142142143142142132132132132132132131131128104103101101100848484838080806968686648494942422622222221212121212121151515777184169156156156130130130120120120008989000
   Retained Earnings Total Equity0000-890,675-880,627-871,468-862,572-852,640000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
21
21
21
21
0
0
0
0
0
0
0
15,071
20,504
20,504
20,504
20,504
20,504
20,504
20,504
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-119,045
0
-125,321
0
0
0
-143,992
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000-143,992000-125,3210-119,04500000000000000000000000000000020,50420,50420,50420,50420,50420,50420,50415,071000000021212121000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
901,546
902,536
903,365
918,942
919,943
0
0
0
0
0000919,943918,942903,365902,536901,546000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
30
33
157
176
65
69
73
82
86
70
79
83
88
114
118
22,460
22,559
22,860
59,031
59,362
44,668
68,524
68,936
69,300
69,674
70,142
70,645
71,026
91,778
90,548
90,889
96,005
119,206
120,141
154,427
154,118
154,319
244,708
257,606
258,392
259,130
309,682
311,231
312,447
332,086
334,332
334,463
335,474
390,114
392,173
393,733
398,585
406,349
571,318
575,364
576,934
579,939
582,400
583,797
582,225
580,567
578,571
622,052
619,232
615,493
613,302
609,247
604,653
651,732
653,817
656,216
774,324
778,953
882,541
884,214
886,033
887,868
891,081
896,390
899,549
900,693
901,546
902,536
903,365
918,942
919,943
920,857
921,583
0
922,058
922,0580921,583920,857919,943918,942903,365902,536901,546900,693899,549896,390891,081887,868886,033884,214882,541778,953774,324656,216653,817651,732604,653609,247613,302615,493619,232622,052578,571580,567582,225583,797582,400579,939576,934575,364571,318406,349398,585393,733392,173390,114335,474334,463334,332332,086312,447311,231309,682259,130258,392257,606244,708154,319154,118154,427120,141119,20696,00590,88990,54891,77871,02670,64570,14269,67469,30068,93668,52444,66859,36259,03122,86022,55922,4601181148883797086827369651761573330000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5
Cost of Revenue-2,315
Gross Profit-2,310-2,310
 
Operating Income (+$)
Gross Profit-2,310
Operating Expense-26,183
Operating Income-28,493-28,493
 
Operating Expense (+$)
Research Development16,279
Selling General Administrative12,219
Selling And Marketing Expenses-2,315
Operating Expense26,18326,183
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,921
Other Finance Cost-888
Net Interest Income-2,809
 
Pretax Income (+$)
Operating Income-28,493
Net Interest Income-2,809
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,140-21,846
EBIT - interestExpense = -30,414
-35,140
-33,219
Interest Expense1,921
Earnings Before Interest and Taxes (EBIT)-28,493-33,219
Earnings Before Interest and Taxes (EBITDA)-26,178
 
After tax Income (+$)
Income Before Tax-35,140
Tax Provision-0
Net Income From Continuing Ops-36,456-35,140
Net Income-35,140
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses28,498
Total Other Income/Expenses Net-6,6472,809
 

Technical Analysis of Alaunos
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alaunos. The general trend of Alaunos is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alaunos's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alaunos Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.51 < 1.65 < 2.03.

The bearish price targets are: 1.34 > 1.2 > 1.05.

Tweet this
Alaunos Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alaunos Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alaunos Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alaunos Therapeutics Inc. The current macd is -0.08051209.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alaunos price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alaunos. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alaunos price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Alaunos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlaunos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alaunos Therapeutics Inc. The current adx is 14.84.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Alaunos shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Alaunos Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alaunos Therapeutics Inc. The current sar is 2.22313884.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Alaunos Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alaunos Therapeutics Inc. The current rsi is 32.30. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Alaunos Therapeutics Inc Daily Relative Strength Index (RSI) ChartAlaunos Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alaunos Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alaunos price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Alaunos Therapeutics Inc Daily Stochastic Oscillator ChartAlaunos Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alaunos Therapeutics Inc. The current cci is -273.42010973.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Alaunos Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAlaunos Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alaunos Therapeutics Inc. The current cmo is -54.14899854.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Alaunos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAlaunos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alaunos Therapeutics Inc. The current willr is -90.625.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Alaunos Therapeutics Inc Daily Williams %R ChartAlaunos Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alaunos Therapeutics Inc. The current atr is 0.17149801.

Alaunos Therapeutics Inc Daily Average True Range (ATR) ChartAlaunos Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alaunos Therapeutics Inc. The current obv is 8,768,924.

Alaunos Therapeutics Inc Daily On-Balance Volume (OBV) ChartAlaunos Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alaunos Therapeutics Inc. The current mfi is 14.29.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Alaunos Therapeutics Inc Daily Money Flow Index (MFI) ChartAlaunos Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alaunos Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Alaunos Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alaunos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.298
Ma 20Greater thanMa 501.760
Ma 50Greater thanMa 1001.873
Ma 100Greater thanMa 2001.660
OpenGreater thanClose1.560
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alaunos with someone you think should read this too:
  • Are you bullish or bearish on Alaunos? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alaunos? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alaunos Therapeutics Inc

I send you an email if I find something interesting about Alaunos Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alaunos Therapeutics Inc.

Receive notifications about Alaunos Therapeutics Inc in your mailbox!